Reply to: Versatility of the clone-censor-weight approach: response to ''trial emulation in the presence of immortal-time bias''

Affiliations

¹ Inequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
² Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.

Comment

Camille Maringe et al. Int J Epidemiol. 2021.

. 2021 May 17;50(2):696.

doi: 10.1093/ije/dyaa225.

¹ Inequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
² Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.

No abstract available

Comment on

Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data.
Maringe C, Benitez Majano S, Exarchakou A, Smith M, Rachet B, Belot A, Leyrat C. Maringe C, et al. Int J Epidemiol. 2020 Oct 1;49(5):1719-1729. doi: 10.1093/ije/dyaa057. Int J Epidemiol. 2020. PMID: 32386426 Free PMC article.
Versatility of the clone-censor-weight approach: response to "trial emulation in the presence of immortal-time bias".
Zhao SS, Lyu H, Yoshida K. Zhao SS, et al. Int J Epidemiol. 2021 May 17;50(2):694-695. doi: 10.1093/ije/dyaa223. Int J Epidemiol. 2021. PMID: 33349843 No abstract available.

1. Zhao SS, Lyu H, Yoshida K.. Versatility of the clone-censor-weight approach: response to “trial emulation in the presence of immortal-time bias”. Int J Epidemiol 2021;50:694–95. - PubMed
1. Maringe C, Benitez Majano S, Exarchakou A. et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol 2020;49:1719–29. - PMC - PubMed